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Introduction
During the Workshop "Pharmacokinetics:
Defining the Dose for Risk Assessment,"
two panel discussions were held. The first
was "Design of Studies to Obtain
Pharmacokinetic Data for Risk Assess-
ment." Emil Pfitzer of Hoffmann-
La Roche, Inc.; James Stevens of
Ciba-Geigy Corporation;Penelope Fenner-
Crisp ofthe U.S. Environmental Protection
Agency Pesticides Program; and Daniel
Menzel of the University of California,
Irvine, were lead discussants. The second
was "How Pharmacokinetics Affects Risk
Assessments in Sensitive Populations,
Especially the VeryYoung and the Elderly"
with Daniel Krewski of the Health and
Welfare Canada, John Doull of the
University of Kansas, Alan Wilson of
Monsanto Company, and Donald
Mattison ofthe University ofPittsburgh as
lead discussants.
The discussions centered around the
following four questions: a) What pharma-
cokinetic data are needed for risk assess-
ment? b) When should pharmacokinetic
data be obtained in toxicity testing? c)
How can pharmacokinetic data be applied
in risk assessment? d) How is pharmacoki-
netics altered in sensitive populations?
WhatPharmacokinetic DataAre
NeededforRiskAssessment?
Pharmacokinetic studies ofpesticides need
to be designed to determine what happens
from the time a person comes into contact
with a pesticide via its most common route
ofexposure until the body's response to the
pesticide is completed. Such studies pro-
vide information on the uptake, distribu-
tion, metabolism, and elimination of
pesticides in the body and on the dose of
toxic metabolites reaching target tissues.
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Once the disposition of low doses of a
compound is established, the effect of
increasing dose on distribution patterns
and excretion routes needs to be deter-
mined. Ofparticular interest is the satura-
tion of metabolic pathways leading to a
nonlinear relationship between the level of
exposure and the dose to the target tissue.
Doses that are lower than those exceeding
the total metabolic capacity of the host
might still be high enough to cause shifts
in metabolic pathways from low capacity
and high affinity enzymes to high capacity
and low affinity enzymes. Such shifts
might greatly influence the toxic effects
exerted by the compound, depending on
the kinetic characteristics of the pathway
leading to formation of the toxic metabo-
lite. Information on the disposition of a
compound as a function ofdose is essential
for evaluating risks to humans exposed at
lowdoses on the basis ofthe results ofani-
mal toxicity studies conducted at high
doses.
The effect of repeated dosing on the
distribution, metabolism, and excretion of
the compound needs to be determined to
evaluate the risks of individuals subject to
multiple exposures over time properly.
These studies are necessary to take into
account the possibility of the induction of
enzymes to either increase or decrease
the level of toxic metabolites. Other
dose-rate effects such as accumulation of
lipid-soluble metabolites in fatty tissues can
also be evaluated in repeated dosing studies.
Basic pharmacokinetic studies, which
are generally conducted in animal models,
need to be done with careful attention to
mass balance. When studying the disposi-
tion of a pesticide, all ofthe material that
entered the animal needs to be accounted
for, either by retention in tissues or by
excretion. Thus, all tissues and excreta
should be analyzed for the presence ofthe
administered compound or its metabolites.
Whole-body radiography can be used to
detect small amounts ofradiolabeled mate-
rial in small organs that might not always
be analyzed.
A major point of discussion was the
consensus tier approach to pharmacoki-
netic studies developed by the Synthetic
Organic Chemical Manufacturers Assoc-
iation's Pharmacokinetics Group and pre-
sented by Alan Wilson. There was some
concern about putting off identification of
metabolites until tier three, although oth-
ers stated that it was logical to determine
whether metabolism of the substance
occurs before attempting to determine the
identity ofmetabolites. In general, the tier
approach was considered appropriate as
long as it is implemented with sufficient
flexibility to take into account different
informational needs for different materials.
WhenShouldPharmacokinetic Data
Be Obtained inToxicityTesting?
Two approaches for using pharmacokinetic
data were discussed. One approach was
using pharmacokinetic data for study
design; the other was using such data for
interpretation ofalready completed studies.
The advantage of doing pharmacokinetic
studies early (say in parallel with short-
term toxicity studies) is that the effects of
dose on the uptake and metabolism of the
compound ofinterest will be known before
setting exposure levels for long-term stud-
ies. Also, secondary mechanisms such as
those described by Eldridge can be
detected in time to avoid the use of an
inappropriate animal model in long-term
studies. For example, if pharmacokinetic
studies indicated that a shift in metabolism
resulting in a marked increase in the for-
mation of toxic compound occurred at
higher doses, it would be desirable to
include an appropriate number ofanimals
below that saturation point in long-term
studies. Ifpharmacokinetic data in inhala-
tion studies indicated that the dose to the
target tissue did not increase because of a
decrease in respiration rate or absorption
above a certain exposure concentration,
higher exposure concentrations would not
be needed in the long-term studies.
The discussants who favored doi-ng
pharmacokinetic studies to aid in interpre-
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tation of the results from previously com-
pleted toxicity studies observed that
detailed pharmacokinetic studies would not
be helpful iftoxicity was not observed. Ifa
nonlinear dose-response relationship is
observed for important toxic end points,
then pharmacokinetic studies can be initi-
ated to determine if the response is the
result ofsaturation ofmetabolic pathways.
Pharmacokinetic studies could be focused
on metabolites in target organs identified
in long-term toxicity studies.
HowCanPharmacokinetic DataBe
Applied inRiskAssessment?
A major point ofdiscussion was how phar-
macokinetic data obtained from manufac-
turers of pesticides might be used by
regulatory agencies. Some participants
questioned whether or not the data would
be used at all. One discussant pointed out
that if the linearized multistage model is
used as a dose-response model for carcino-
genesis, internal-dose considerations are
easily incorporated into the model for risk
assessment purposes. Representatives ofthe
U.S. EPA Pesticides Program pointed out
that their institutional philosophy was to
go beyond the series ofdefault assumptions
concerning mechanisms that are used in
risk assessment and reflect biological reality
based on scientific knowledge. Therefore,
pharmacokinetic data would be useful in
the regulatory process. A standardized
approach to pharmacokinetic studies such
as the consensus tier approach would be
helpful for regulatory applications ofphar-
macokinetic data. However, concerns
about the additional costs ofsuch studies
were raised. Others pointed out that the
costs of obtaining pharmacokinetic data
were much smaller than long-term chronic
studies, and the data provided essential
information for designing or interpreting
chronic studies.
Representatives ofpharmaceutical com-
panies identified five types ofpharmacoki-
netic data that are normally used to assess
drugs. These are bioavailability, dose pro-
portionality, the effect ofrepeated dosing,
metabolism ofthe compound, and the rela-
tionship between blood or tissue levels and
toxicity. This information is needed to
evaluate the effects ofpesticides as well as
drugs, although assessment is more difficult
for pesticides than for drugs. For pharma-
ceutical agents, scientists know exactly how
much ofthe agent is administered and they
can go quickly from preclinical studies to
studies in humans. Detailed studies in
humans are not possible for pesticides.
There is also a defined route of exposure
for pharmaceutical agents: people can be
exposed to pesticides via ingestion, dermal
absorption, and inhalation.
Mathematical models were considered
by panelists to be a powerful tool for appli-
cation of pharmacokinetic data. Models
describing the pharmacokinetics ofchemi-
cals can be developed in animals and, with
appropriate scaling techniques, can be
used to predict the pharmacokinetic behav-
ior of the same compound in humans.
Biologically based models, which include
appropriate physiological, biochemical, and
metabolic parameters, provide a useful
framework for describing the kinetics of
distribution ofa compound or its metabo-
lites in the body. Such physiologically
based pharmacokinetic models sometimes
are most useful when the data do not fit
the model. In this case, the investigator
must try to determine what is missing from
the model and develop a modified model
that adequately describes the data. The
exercise of model building and model
refinement often provides useful insight
into pharmacokinetic processes involved in
the handling ofxenobiotics by the body. In
the work by Gearhart et al., the modeling
process was carried one step further by
melding the modeling ofpharmacokinetic
and pharmacodynamic data. They indi-
cated that such an integrated biologically
based modeling approach can provide a
more complete description ofthe sequence
ofevents leading to a toxic response to pes-
ticide exposure.
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Howis PharamacokineticsAltered in
Sensitive Populations?
The panelists discussed the differences
between children and adults in exposure to
pesticides and in the rate ofmetabolism or
clearance of the compound. Children are
exposed to different amounts ofpesticides
by ingestion than are older persons. Studies
at the University of Pittsburgh indicate
that human breast milk is more contami-
nated with pesticides than cow's milk,
although the degree of contamination of
breast milk has gone down since 1986 (1).
On a body weight basis, children are
known to eat or drink more of certain
foods or beverages such as apple juice than
adults do (Figure 1). Therefore, in deter-
mining the potential dosimetry ofchildren
to pesticide-contaminated food, the
increased intake ofcertain food products in
children must be considered.
Information from studies on blood lev-
els ofadministered cancer chemotherapeu-
tic agents, such as those conducted at St.
Jude's Hospital as reported by Crom, indi-
cates that children metabolize and clear
xenobiotics faster than adults. That also has
been documented in a 1992 report from
the International Life Sciences Institute
entitled Similarities and Differences in
Children and Adults: Implications for Risk
Assessment. One discussant referred to the
work of an Interagency Pharmacokinetics
Group, a consortium ofscientists from the
Food and Drug Administration; the EPA;
Consumer Product Safety Commission;
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Figure 1. Body weight-adjusted food consumption (data from U.S. EPA's Tolerance Assessment System, based on
USDA survey). USDA (U.S. Department of Agriculture). 1983. Nationwide Food Consumption Survey. Nutrient
Intakes: Individuals in 48 States, Year 1977-78. Report No. I-1. Hyattsville, MD: Consumer Nutrition Division,
Human Nutrition Information Service.
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and the Occupational Safety and Health
Administration, who reported that the
ratio ofliver to body weight is high in chil-
dren. Thus, children may clear some chem-
icals faster than adults because clearance of
some drugs is dependent on total liver
mass.
Another factor that must be taken into
account is the nutritional status ofexposed
people. It is well known that undernour-
ished children or elderly persons have a
decreased ability to mount and maintain
normal immune response and thus they
respond poorly to vaccination procedures
that are effective in well-nourished chil-
dren. Undernourished people also have less
defense against toxic materials than well-
nourished individuals because ofdecreased
host defense mechanisms.
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